<DOC>
	<DOCNO>NCT02073929</DOCNO>
	<brief_summary>Polycystic ovary syndrome ( PCOS ) affect 5-10 % woman fertile age . PCOS associate metabolic syndrom , diabetes increase risk og cardiovascular disease . The study investigate effect af intervention GLP-1-analog risk marker cardiovascular disease woman PCOS . 70 woman include af RCT . Hypothesis : GLP-1-analog treatment woman PCOS ( without diabetes ) result beneficial reduction risk marker vascular thrombosis early cardiovascular disease .</brief_summary>
	<brief_title>LIPT - Liraglutide Polycystic Ovary Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Polycystic Ovary Syndrome</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>PCOS &gt; 18 year premenopausal BMI &gt; 25 og 25 thereunder + insulin resistent Exclusion Criteria ( include ) : actualt intend pregnancy inadeqvat contraception hormonal contraception within 6 week metfoomin , GLP1analog DPP IV inhibitor within 3 month medication affectiv hemostatic mechanisme diabetes severe comorbidity familar MEN</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>